SCHEMBL1358402

SCHEMBL1358402

CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CCC4CC(O)CC[C@]4(C)[C@H]3CC[C@]12C

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPBAR1 Q8TDU6 8/20 0.76
EPHA2 P29317 4/20 0.76
CASP7 P55210 3/20 0.76
HIF1A Q16665 3/20 0.76
VDR P11473 3/20 0.76
TP53 P04637 2/20 0.76
MAPK1 P28482 2/20 0.76
HSD17B10 Q99714 2/20 0.76
BLM P54132 2/20 0.76
TDP1 Q9NUW8 2/20 0.76
USP2 O75604 2/20 0.76
LMNA P02545 2/20 0.76
CYP3A4 P08684 2/20 0.76
MDM4 O15151 1/20 0.76
MAPT P10636 1/20 0.76
HSPD1 P10809 1/20 0.76
TSHR P16473 1/20 0.76
PTPN2 P17706 1/20 0.76
PTPN1 P18031 1/20 0.76
BRCA1 P38398 1/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30594199 1.00 GPBAR1 (0.76) GPBAR1EPHA2CASP7HIF1AVDR
SCHEMBL7915341 1.00 GPBAR1 (0.76) GPBAR1EPHA2CASP7HIF1AVDR
SCHEMBL15292960 1.00 GPBAR1 (0.76) GPBAR1EPHA2CASP7HIF1AVDR
SCHEMBL14983111 1.00 GPBAR1 (0.76) GPBAR1EPHA2CASP7HIF1AVDR
SCHEMBL13356169 1.00 GPBAR1 (0.76) GPBAR1EPHA2CASP7HIF1AVDR
SCHEMBL15185969 1.00 GPBAR1 (0.76) GPBAR1EPHA2CASP7HIF1AVDR
SCHEMBL20392723 1.00 GPBAR1 (0.76) GPBAR1EPHA2CASP7HIF1AVDR
SCHEMBL13588005 1.00 GPBAR1 (0.76) GPBAR1EPHA2CASP7HIF1AVDR
SCHEMBL13811486 1.00 GPBAR1 (0.76) GPBAR1EPHA2CASP7HIF1AVDR
SCHEMBL15185970 1.00 GPBAR1 (0.76) GPBAR1EPHA2CASP7HIF1AVDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4133266-A1 IMPROVED METHODS FOR EVALUATING LIVER FUNCTION Hepquant, LLC (US) 2023-02-15 EP claimed
US-20210318274-A1 METHODS FOR EVALUATING LIVER FUNCTION HepQuant, LLC 2021-10-14 US claimed
CN-109831915-A TLR 9-targeted spherical nucleic acid with strong anti-tumor activity 埃克西奎雷股份有限公司 2019-05-31 CN claimed
US-6071670-A PHOTORESIST RESIN COMPRISING PHOTOACID GENERATING COMPOUND AND AN ACID HYDROLYZABLE OLIGOMER HAVING ALICYCLIC OR POLYCONDENSED AROMATIC BACKBONE; ALKALI DEVELOPMENT WITH HIGH RESOLUTION, DRY ETCH RESISTANCE KABUSHIKI KAISHA TOSHIBA (JP) 2000-06-06 US claimed
CN-114942292-B Method for detecting content of plant sterol substances in blood based on liquid chromatography-tandem mass spectrometry technology 中国医学科学院阜外医院 2023-09-12 CN disclosed
EP-4133266-A1 IMPROVED METHODS FOR EVALUATING LIVER FUNCTION Hepquant, LLC (US) 2023-02-15 EP disclosed
CN-114942292-A Method for detecting content of phytosterol substances in blood based on liquid chromatography-tandem mass spectrometry technology 中国医学科学院阜外医院 2022-08-26 CN disclosed
US-20210318274-A1 METHODS FOR EVALUATING LIVER FUNCTION HepQuant, LLC 2021-10-14 US disclosed
CN-109831915-A TLR 9-targeted spherical nucleic acid with strong anti-tumor activity 埃克西奎雷股份有限公司 2019-05-31 CN disclosed
CN-206192957-U Test system and preceding processing apparatus of sample of synthetic absorption marker thing of cholesterol 杭州量康科技有限公司 2017-05-24 CN disclosed
US-20120009122-A1 GASTRIN RELEASING PEPTIDE COMPOUNDS BRACCO IMAGING S.P.A. (IT) 2012-01-12 US disclosed
US-20110280802-A1 Linkers For Radiopharmaceutical Compounds BRACCO IMAGING S.P.A. (IT) 2011-11-17 US disclosed
US-20100009927-A1 Anti-Inflammatory and Anti-Allergy Extracts from Nettle HERBALSCIENCE GROUP LLC (US) 2010-01-14 US disclosed
CN-100543136-C Seed-specific USP promoter for expressing genes in plants MONSANTO TECHNOLOGY LLC (US) 2009-09-23 CN disclosed
US-20080200439-A1 Establishing a test sample comprising a myocyte BK channel beta 1 subunit and measuring the interaction, effect, or combination thereof, of a candidate composition on test sample to thereby determine ability of candidate composition to modulate myocyte BK channel activity UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2008-08-21 US disclosed
WO-2008085492-A2 METHODS AND COMPOSITIONS FOR MODULATING BK CHANNEL ACTIVITY AND VASODILATION UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2008-07-17 WO disclosed
CN-1728937-A Time-specific seed promoters for expressing genes in plants MONSANTO TECHNOLOGY LLC (US) 2006-02-01 CN disclosed
CN-1685040-A Seed-specific USP promoter for expressing genes in plants MONSANTO TECHNOLOGY LLC (US) 2005-10-19 CN disclosed
US-6071670-A PHOTORESIST RESIN COMPRISING PHOTOACID GENERATING COMPOUND AND AN ACID HYDROLYZABLE OLIGOMER HAVING ALICYCLIC OR POLYCONDENSED AROMATIC BACKBONE; ALKALI DEVELOPMENT WITH HIGH RESOLUTION, DRY ETCH RESISTANCE KABUSHIKI KAISHA TOSHIBA (JP) 2000-06-06 US disclosed
EP-0331477-A2 Organic dye thin film and organic thin film element KABUSHIKI KAISHA TOSHIBA (JP) 1989-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120009122-A1 GASTRIN RELEASING PEPTIDE COMPOUNDS GRPR, GIPR, CCKBR GPBAR1 9/4885EPHA2 756/4885CASP7 2962/4885
US-20110280802-A1 Linkers For Radiopharmaceutical Compounds VIP, QPCT, NPPA GPBAR1 3590/4885EPHA2 1644/4885CASP7 2519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.